US20230310513A1 - Method for feeding a flatworm and flatworm extract free of human-pathogenic microorganisms - Google Patents
Method for feeding a flatworm and flatworm extract free of human-pathogenic microorganisms Download PDFInfo
- Publication number
- US20230310513A1 US20230310513A1 US18/024,682 US202118024682A US2023310513A1 US 20230310513 A1 US20230310513 A1 US 20230310513A1 US 202118024682 A US202118024682 A US 202118024682A US 2023310513 A1 US2023310513 A1 US 2023310513A1
- Authority
- US
- United States
- Prior art keywords
- extract
- human
- flatworms
- flatworm
- yeast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000242594 Platyhelminthes Species 0.000 title claims abstract description 149
- 239000000284 extract Substances 0.000 title claims abstract description 124
- 238000000034 method Methods 0.000 title claims abstract description 50
- 244000005700 microbiome Species 0.000 title claims abstract description 44
- 241000397921 Turbellaria Species 0.000 claims description 92
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 84
- 239000000203 mixture Substances 0.000 claims description 44
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 241001325293 Schmidtea mediterranea Species 0.000 claims description 18
- 230000035876 healing Effects 0.000 claims description 15
- 210000005260 human cell Anatomy 0.000 claims description 14
- 238000001228 spectrum Methods 0.000 claims description 14
- 244000000010 microbial pathogen Species 0.000 claims description 11
- 241001528273 Acinetobacter guillouiae Species 0.000 claims description 9
- 241000607528 Aeromonas hydrophila Species 0.000 claims description 9
- 241000589518 Comamonas testosteroni Species 0.000 claims description 9
- 241001600125 Delftia acidovorans Species 0.000 claims description 9
- 241000191938 Micrococcus luteus Species 0.000 claims description 9
- 241000589540 Pseudomonas fluorescens Species 0.000 claims description 9
- 241001147736 Staphylococcus capitis Species 0.000 claims description 9
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 9
- 241000191984 Staphylococcus haemolyticus Species 0.000 claims description 9
- 229940037649 staphylococcus haemolyticus Drugs 0.000 claims description 9
- 241000736110 Sphingomonas paucimobilis Species 0.000 claims description 8
- 210000004102 animal cell Anatomy 0.000 claims description 8
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 claims description 8
- 241000607574 Aeromonas veronii Species 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 241001330860 Rhabditophora Species 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 3
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 3
- 210000001161 mammalian embryo Anatomy 0.000 claims description 3
- 231100000075 skin burn Toxicity 0.000 claims description 3
- 206010072170 Skin wound Diseases 0.000 claims description 2
- 239000002537 cosmetic Substances 0.000 abstract description 9
- 239000002417 nutraceutical Substances 0.000 abstract description 6
- 235000021436 nutraceutical agent Nutrition 0.000 abstract description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 78
- 210000004027 cell Anatomy 0.000 description 46
- 239000006286 aqueous extract Substances 0.000 description 34
- 230000035611 feeding Effects 0.000 description 30
- 210000000130 stem cell Anatomy 0.000 description 28
- 235000013305 food Nutrition 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 17
- 210000002919 epithelial cell Anatomy 0.000 description 17
- 238000010790 dilution Methods 0.000 description 16
- 239000012895 dilution Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 15
- 241000282412 Homo Species 0.000 description 14
- 244000309466 calf Species 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- 238000000605 extraction Methods 0.000 description 13
- 210000002889 endothelial cell Anatomy 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 241000736262 Microbiota Species 0.000 description 11
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 230000003902 lesion Effects 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 238000005259 measurement Methods 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 241000242531 Dugesia japonica Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 244000000007 bacterial human pathogen Species 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 241000607534 Aeromonas Species 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 240000002900 Arthrospira platensis Species 0.000 description 3
- 235000016425 Arthrospira platensis Nutrition 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010051246 Photodermatosis Diseases 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 235000013527 bean curd Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000008845 photoaging Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000013322 soy milk Nutrition 0.000 description 3
- 229940082787 spirulina Drugs 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000242722 Cestoda Species 0.000 description 2
- 241000611330 Chryseobacterium Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101001054921 Homo sapiens Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241001660097 Pedobacter Species 0.000 description 2
- 241000620655 Pseudomonas brenneri Species 0.000 description 2
- 241001312498 Pseudomonas gessardii Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000006750 UV protection Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000019846 buffering salt Nutrition 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002687 nonaqueous vehicle Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 241000495248 Acidovorax wautersii Species 0.000 description 1
- 241001528276 Acinetobacter bereziniae Species 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108091012583 BCL2 Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000206604 Brochothrix thermosphacta Species 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 241000611327 Chryseobacterium scophthalmum Species 0.000 description 1
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 description 1
- 241000464739 Comamonas aquatilis Species 0.000 description 1
- 241000334665 Corynebacterium lipophiloflavum Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001528536 Ensifer adhaerens Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102100037316 F-box/LRR-repeat protein 4 Human genes 0.000 description 1
- 241000242711 Fasciola hepatica Species 0.000 description 1
- 241000523886 Flavobacterium oncorhynchi Species 0.000 description 1
- 241001601965 Flavobacterium tructae Species 0.000 description 1
- 108010009306 Forkhead Box Protein O1 Proteins 0.000 description 1
- 102100035427 Forkhead box protein O1 Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101001026867 Homo sapiens F-box/LRR-repeat protein 4 Proteins 0.000 description 1
- 101001026853 Homo sapiens F-box/LRR-repeat protein 5 Proteins 0.000 description 1
- 101001081176 Homo sapiens Hyaluronan mediated motility receptor Proteins 0.000 description 1
- 101000864800 Homo sapiens Serine/threonine-protein kinase Sgk1 Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 102100027735 Hyaluronan mediated motility receptor Human genes 0.000 description 1
- 241001148465 Janthinobacterium Species 0.000 description 1
- 241000194039 Lactococcus piscium Species 0.000 description 1
- 241001633954 Microbacterium oxydans Species 0.000 description 1
- 241000891338 Micrococcus yunnanensis Species 0.000 description 1
- 241000194105 Paenibacillus polymyxa Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000833549 Pedobacter wanjuense Species 0.000 description 1
- 241001533308 Polycelis nigra Species 0.000 description 1
- 241000520869 Pseudomonas anguilliseptica Species 0.000 description 1
- 241000218935 Pseudomonas azotoformans Species 0.000 description 1
- 241001497665 Pseudomonas frederiksbergensis Species 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 241000556569 Rhizobium giardinii Species 0.000 description 1
- 102100030070 Serine/threonine-protein kinase Sgk1 Human genes 0.000 description 1
- 241001135258 Serratia proteamaculans Species 0.000 description 1
- 241001053777 Shinella zoogloeoides Species 0.000 description 1
- 241001178538 Sphingomonas bisphenolicum Species 0.000 description 1
- 241001644791 Sphingomonas ginsenosidimutans Species 0.000 description 1
- 241000192087 Staphylococcus hominis Species 0.000 description 1
- 241000244155 Taenia Species 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 241000242541 Trematoda Species 0.000 description 1
- 241000869417 Trematodes Species 0.000 description 1
- 241001125330 Urmitella Species 0.000 description 1
- 241001478284 Variovorax paradoxus Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241000580495 Vogesella Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007609 bcye-agar Substances 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000007382 columbia agar Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 208000006275 fascioliasis Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- -1 flakes Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000001196 time-of-flight mass spectrum Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000003563 vegetarian diet Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
- A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
- A01K67/0335—Genetically modified worms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0601—Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/25—Animals on a special diet
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/70—Invertebrates
- A01K2227/703—Worms, e.g. Caenorhabdities elegans
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
Definitions
- the present invention relates to a method for feeding a flatworm and to a flatworm extract that is free of human-pathogenic microorganisms, useful in the pharmaceutical, cosmetic and nutraceutical fields.
- flatworms designates a phylum of tapeworms which includes four classes: the rhabditophora (formerly “turbellarians”) such as the planarian, the monogeneans which are parasites of aquatic organisms, the trematodes (flukes, digeneans) which are parasites such as liver fluke, and cestodes such as tape worm or taenia.
- the rhabditophora originally “turbellarians”
- monogeneans which are parasites of aquatic organisms
- trematodes flukes, digeneans
- cestodes such as tape worm or taenia.
- Planarians are aquatic tapeworms belonging to several species in the class of Rhabditophora. They can be swimmers or crawlers, and live at sea, in fresh water, or in very humid soils (in tropical forests). Planarians are known for their regenerative abilities. They are able to perpetually regenerate themselves, and any part of their body, due to the presence of a large amount of stem cells (20-30%) in their tissues compared to other living organisms for which the amount of stem cells is of the order of 1 ppm. Planarian stem cells multiply and regenerate continuously, unlike the stem cells of more evolved organisms, which multiply little or not at all. The biochemical factors allowing the multiplication of stem cells in a planarian remain unidentified.
- Flatworms are known to feed on substances of animal origin in their natural environment, and are generally fed with calf liver or chicken liver when reared in the laboratory. Because of their diet, flatworms harbor human-pathogenic microorganisms in their microbiota.
- Patent application WO2019016346 describes a planarian aqueous extract, which is non-parasitic and non-pathogenic in humans, in particular of the Schmidtea mediterranea species, capable of activating the multiplication of human stem cells and which therefore has a cell regeneration activity useful in numerous cosmetic, pharmaceutical or nutraceutical applications.
- the flatworms used to obtain flatworm extracts are generally fed with calf liver.
- the analysis of their microbiota revealed the presence of human-pathogenic microorganisms, such as Aeromonas veronii, Staphylococcus capitis, Pseudomonas fluorescens, Acinetobacter guillouiae, Aeromonas hydrophila, Delftia acidovorans, Comamonas testosteroni, Sphingomonas paucimobilis, Staphylococcus epidermidis, Micrococcus luteus and/or Staphylococcus haemolyticus.
- human-pathogenic microorganisms such as Aeromonas veronii, Staphylococcus capitis, Pseudomonas fluorescens, Acinetobacter guillouiae, Aeromonas hydrophila, Delftia acidovorans, Comamonas testosteroni, Sphingomon
- microorganisms can be problematic in all cosmetic, pharmaceutical or nutraceutical applications resulting from the use of flatworm extracts or flatworms as such.
- a first object of the present invention relates to a method for feeding flatworms, in which the flatworms are fed exclusively with malted yeast.
- a second object of the present invention relates to a method for preparing a flatworm extract, comprising the steps of:
- a third object of the present invention relates to a flatworm extract fed exclusively with malted yeast capable of being obtained by implementing the method according to the second object of the invention, said flatworms being free of human-pathogenic microorganisms.
- a fourth object of the present invention relates to a composition
- a composition comprising one or more flatworms fed exclusively with malted yeast, said flatworm(s) being free of human-pathogenic microorganisms.
- a fifth object of the present invention relates to a composition comprising an extract according to the invention.
- a sixth object of the present invention relates to a method for eliminating pathogenic microorganisms present in one or more flatworms, said method comprising a step which consists in feeding one or more flatworms, preferably exclusively, with malted yeast for a sufficient period to eliminate said pathogenic microorganisms.
- a seventh object of the present invention relates to a method for preparing a flatworm extract according to the invention, comprising the steps of: (a) obtaining flatworms free of human-pathogenic microorganisms by implementing the method for eliminating pathogenic microorganisms from flatworms according to the invention; (b) preparing a flatworm extract from the flatworms obtained in step (a).
- An eighth object of the present invention relates to the use of an aqueous extract according to the invention or of a composition comprising an extract according to the invention, for cultivating human or animal cells in vitro or ex vivo.
- a ninth object of the present invention relates to an extract according to the invention or a composition comprising an extract according to the invention, for the use thereof as a medicament, for example to be used to promote the healing of a wound in the skin or a skin burn.
- the term “flatworm” refers to a flatworm from the phylum of the same name.
- the flatworm can be of the class of rhabditophora, preferably it is a planarian.
- the flatworm according to the invention is non-parasitic and/or non-pathogenic in humans.
- the flatworm according to the invention is a planarian belonging to one of the following species Schmidtea mediterranea, Dugesia japonica, Dendricoelum lacteum, Polycelis nigra, Polycelys tenuis and planarian torva , preferably to Schmidtea mediterranea species.
- Malted yeast or “brewer's yeast” is well described in the literature, it is the result of growing Saccharomyces cerevisiae with malt, usually barley malt. It usually comes in the form of flakes and is widely used in vegetarian diets.
- the malted yeast according to the present invention can be in any form suitable for feeding flatworms, for example in the form of powder, flakes, granules or in liquid form, for example obtained by mixing flakes with water.
- the yeasts present in the malted yeast are said to be “active”, that is to say they are alive.
- flatworm free of human-pathogenic microorganisms designates a flatworm whose digestive tract is free of human-pathogenic microorganisms, that is to say a flatworm whose microbiota is free of human-pathogenic microorganisms.
- the human-pathogenic microorganisms are Aeromonas veronii, Staphylococcus capitis, Pseudomonas fluorescens, Acinetobacter guillouiae, Aeromonas hydrophila, Delftia acidovorans, Comamonas testosteroni, Sphingomonas paucimobilis, Staphylococcus epidermidis, Micrococcus luteus and Staphylococcus haemolyticus .
- the microbiota of the flatworm of the invention is therefore free of the set of pathogenic microorganisms mentioned above.
- extract designates the product resulting from the extraction of the contents of the cells.
- extract of one or more flatworms designates the product resulting from the extraction of the contents of the cells of said flatworm(s).
- a “pharmaceutically acceptable” means approved by a federal or state regulatory agency or listed in the United States or European Pharmacopoeia, or other generally recognized pharmacopoeia, for use in animals and humans.
- a “pharmaceutical composition” means a composition comprising a pharmaceutically acceptable vehicle.
- a pharmaceutically acceptable vehicle can be a diluent, adjuvant, excipient, or vehicle with which the therapeutic agent is administered.
- These vehicles can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. Saline solutions and aqueous solutions of dextrose and glycerol can also be used as liquid vehicles, especially for injection solutions.
- compositions comprise starch, glucose, lactose, sucrose, sodium stearate, glycerol monostearate, talc, sodium chloride, skimmed milk powder, glycerol, propylene glycol, water, ethanol and the like.
- the tablets or capsules can be prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (for example pregelatinized corn starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (for example lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (for example, magnesium stearate, talc or silica); disintegrants (for example potato starch or sodium starch glycolate); or wetting agents (for example, sodium lauryl sulfate).
- binding agents for example pregelatinized corn starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
- fillers for example lactose, microcrystalline cellulose or calcium hydrogen phosphate
- lubricants for example, magnesium stearate, talc or silica
- disintegrants for example potato starch or sodium starch glycolate
- wetting agents for example, sodium lauryl sulfate
- Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or may be presented as a dry product to be reconstituted with water or another suitable vehicle before use.
- Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable vehicles such as suspending agents (for example sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (for example, lecithin or acacia); non-aqueous vehicles (for example almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (for example methyl or propyl p-hydroxybenzoates or sorbic acid).
- the pharmaceutical compositions may also contain buffering salts, flavoring agents, dyes and sweeteners, as appropriate.
- treating encompasses any beneficial or desirable effect on a pathology or pathological condition, and may even include minimal reduction of one or more measurable markers of the pathology or pathological condition.
- the treatment may, for example, involve either reducing or improving the symptoms of the pathology or pathological condition, or delaying the progression of the pathology or pathological condition.
- treatment does not necessarily mean the complete eradication or cure of the pathology, nor of the associated symptoms.
- the description relates to a flatworm fed exclusively with malted yeast, said flatworm being free of human-pathogenic microorganisms.
- the inventors realized that flatworms fed exclusively with malted yeast were free of human-pathogenic microorganisms, whereas flatworms fed with conventional food, such as calf liver, or even fed with baker's yeast ( Saccharomyces cerevisiae ), develop human-pathogenic microorganisms in their digestive tract.
- the inventors have therefore shown that it suffices to feed flatworms exclusively with malted yeast to obtain flatworms free of human-pathogenic microorganisms.
- the present invention does not require the use of antibiotics to obtain flatworms free of human-pathogenic microorganisms.
- the flatworms of the present description are therefore not only free of human-pathogenic microorganisms, but also free of antibiotics.
- Flatworms can be alive or dead. It can for example be frozen, freeze-dried and/or dried.
- the flatworm is advantageously free of the following human-pathogenic microorganisms: Aeromonas veronii, Staphylococcus capitis, Pseudomonas fluorescens, Acinetobacter guillouiae, Aeromonas hydrophila, Delftia acidovorans, Comamonas testosteroni, Sphingomonas paucimobilis, Staphylococcus epidermidis, Micrococcus luteus and Staphylococcus haemolyticus.
- the invention also relates to a composition
- a composition comprising one or more flatworms fed exclusively with malted yeast, said flatworm(s) being free of human-pathogenic microorganisms.
- compositions comprising the flatworm(s) in their environment, for example a composition comprising water, at least one flatworm according to the invention and optionally malted yeast. It may for example be a composition comprising one or more flatworms according to the present description and exclusively malted yeast as food for the flatworm(s).
- composition can be in various forms, for example in liquid form or in freeze-dried form.
- the composition may additionally comprise a lyoprotectant, such as an unnatural lyoprotectant.
- An object of the present invention relates to a method for feeding flatworms, in which the flatworms are fed exclusively with malted yeast.
- flatworms refuse to feed on a long-term basis with malt or baker's yeast ( Saccharomyces cerevisiae )
- the Applicant has demonstrated that flatworms accept to feed on a long-term basis with malted yeast ( Saccharomyces cerevisiae with malt).
- Flatworms agree to feed exclusively with malted yeast, which advantageously allows to obtain flatworms not only free of human-pathogenic microorganisms but also free of element of animal origin.
- the feeding method according to the invention comprises a step which consists in feeding the flatworms for a sufficient time to eliminate the human-pathogenic microorganisms and/or eliminate the elements of animal origin.
- the flatworms are fed at least once a week, preferably at least twice a week, with an amount of malted yeast ranging from 0.10 mg of yeast/400 flatworms to 0.20 mg of yeast/400 flatworms, preferably an amount of 0.15 mg yeast/400 flatworms.
- Flatworms are fed for the time necessary to be free of human-pathogenic microorganisms.
- the flatworms are fed for at least one week, preferably for at least 2 weeks, for example for 4 weeks.
- the flatworms are deprived of all food for at least one week before being fed with the malted yeast.
- Another object of the present invention relates to a method for preparing a flatworm extract, comprising the steps of:
- Step (ii) of preparing the extract is described in more detail in the “flatworm extract” section below.
- Another object of the invention relates to a flatworm extract fed exclusively with malted yeast which can be obtained by implementing the method for preparing a flatworm extract according to the invention, said flatworms being free of human-pathogen microorganisms.
- the extract according to the invention can for example be an aqueous extract.
- the extract according to the invention is free of antibiotics.
- the absence of antibiotic within the extract according to the invention makes it particularly suitable for use in humans or animals.
- the extract according to the invention is free of elements of animal origin other than those relating to the flatworm itself. This advantageously allows to have an extract that is particularly suitable for use in vegan products, that is to say products not comprising any ingredient of animal origin, such as vegan cosmetic products.
- the preparation of a flatworm extract does not have any particular difficulty, numerous extraction methods being described in the literature.
- the preparation of a flatworm extract is not limited to a particular method, and the conventional methods can be implemented to prepare an extract according to the invention, such as for example by implementing a method comprising the following steps: (i) grinding flatworms in order to obtain a ground material, (ii) ridding the ground material of insoluble solid debris in order to obtain an extract, and (iii) optionally concentrating or diluting the extract.
- Step (i) can be implemented with any grinding method allowing to burst the flatworm cells and to release their contents, for example by shaking flatworms with glass beads.
- Step (ii) can be implemented by centrifuging and/or filtering the ground material.
- the extract according to the invention is cleared of any insoluble solid debris, in particular cleared of membrane debris resulting from the bursting of flatworm cells.
- the preparation method may comprise at least one solid/liquid separation step, for example one or more membrane filtration steps having an appropriate cut-off threshold, for example a cut-off threshold of 1.20 ⁇ m, for example 0.80 ⁇ m, 0.45 ⁇ m, 0.2 ⁇ m.
- Filtration allows to obtain an extract which contains particles of a size less than the cut-off threshold of the filter used, for example particles of a size of less than 1.20 ⁇ m, for example less than 0.80 ⁇ m, less than 0.45, less than ⁇ m 0.2 ⁇ m.
- Step (iii) can be implemented by evaporation or by adding a suitable solvent, for example water.
- Example 3 describes a method for preparing a flatworm extract according to the invention.
- the extraction conditions will be chosen such that the extract obtained has the desired concentration in the intended application.
- the protein concentration of the crude extract can vary in particular depending on the amount of flatworm used (for example, during an aqueous extraction, when the ratio flatworm/water is increased, the protein concentration of the extract also increases), the extraction time (for example, an increase in the extraction time during an aqueous extraction generally allows to increase the protein concentration of the extract) and/or the extraction temperature (for example, an increase in the extraction temperature during an aqueous extraction generally allows to increase the protein concentration of the extract).
- the crude extract comprises from 1 mg to 50 mg of proteins per mL of extract (mg/mL).
- the absorbance at the characteristic wavelength of 280 nm that is to say A280 nm) is commonly used to estimate the total protein concentration in the extract.
- the extract obtained can be more or less concentrated in proteins depending on the intended use.
- the extract may in particular comprise between 15 mg of protein per mL of extract (mg/mL) and 20 mg/mL.
- the crude extract can be diluted or even concentrated depending on the intended use.
- the extract according to the invention comprises from 15 ⁇ g of protein per mL of extract ( ⁇ g/mL) to 50 mg of protein per mL of extract (mg/mL), for example from 15 ⁇ g/mL to 20 mg/L, for example from 15 ⁇ g/mL to 1 mg/L, for example from 15 ⁇ g/mL to 0.3 mg/L.
- the extract according to the invention comprises less than 0.5 mg of protein per mL of extract (mg/mL), for example less than 0.3 mg/mL, for example between 15 ⁇ g/mL and 0.3 mg/mL, preferably 15 ⁇ g mg/mL to 75 ⁇ g/mL. Complete dehydration of this extract allows to obtain an extract in powder form.
- the extract according to the invention has a MALDI TOF spectrum corresponding to the data shown in Table 1.
- Extract 1 Extract 2 Extract 3 m/z Intensity S/N m/z Intensity S/N m/z Intensity.
- S/N 2001 5051 8 2000.7 5566 8 2001.2 1706 7 2390.4 3699 5 2723.3 3988 7 2723.8 2062 9 2723.7 4012 8 3335.8 3074 5 3335.7 1224 5 3335.6 2812 5 3672.7 3390 7 3673.2 2021 9 3673.3 3533 9 3708.1 4153 10 3708.4 2804 13 3708.7 4596 13 4551.1 2822 7 3760.5 1500 7 3760.9 2701 6 4871.2 3613 10 4550.7 1414 7 4551.4 2604 7 5012.3 2930 8 4871.1 2254 11 4871.6 3185 10 5072.5 3321 9 5012.6 1683 9 5012.9 2746 8 5267.7 2351 6 5060 974 5 5060.4 2042 5 5646.8 7211 28 5072.8 2096 11 5072.8 3282 10 5870.1 2197 6 5268 1410 7
- composition Comprising a Flatworm Extract
- the invention also relates to a composition comprising an extract according to the invention.
- the composition is a cosmetic and/or dermatological composition and may comprise one or more carriers and/or excipients suitable for the targeted use.
- the composition can be in the form of a gel, lotion, cream, ointment, paste or soap.
- the composition according to the invention may comprise various usual excipients suitable for external topical administration, in particular excipients that are dermatologically and/or cosmetologically acceptable.
- excipients suitable for the formulation are well known to the person skilled in the art and comprise, for example, agents promoting penetration at the skin, moisturizing agents, thickening agents, stabilizing agents, emollient agents and surfactants, emulsifying agents, preservatives, pH adjusting agents, etc.
- the composition according to the invention is formulated in the form of a cream comprising the extract of the invention and at least the following excipients: an emulsifying agent, an emollient agent, a thickening agent, a moisturizing agent and optionally a preservative.
- the composition according to the invention is formulated in the form of a cream comprising the extract of the invention and at least the following additional excipients: a gelling agent, a thickening agent, a moisturizing agent and optionally a preservative.
- composition according to the invention may also comprise other compounds suitable for cosmetic and/or dermatological use, such as radical scavengers, antioxidant vitamins such as vitamin E, vitamin C, antioxidant agents such as natural polyphenols, enzymes, plant active ingredients, natural anti-inflammatory substances, alcohols, polyols, esters, electrolytes, polar and non-polar oils, polymers, copolymers, phospholipids, dyes, perfumes and/or skin peeling agents.
- radical scavengers such as vitamin E, vitamin C
- antioxidant agents such as natural polyphenols, enzymes, plant active ingredients, natural anti-inflammatory substances, alcohols, polyols, esters, electrolytes, polar and non-polar oils, polymers, copolymers, phospholipids, dyes, perfumes and/or skin peeling agents.
- the composition is a nutraceutical composition (or food supplement) and may comprise one or more carriers and/or excipients suitable for the targeted use.
- the composition must therefore be able to be ingested. It can be in different dosage forms, such as a dispersion, a capsule, a cachet, a powder, a tablet, etc.
- the nutraceutical composition can also be in the form of a food, such as a yoghurt, a cereal bar, a gel, a candy, a chewing gum, etc.
- the composition is a pharmaceutical composition and may comprise a pharmaceutically acceptable vehicle.
- Pharmaceutically acceptable excipients comprise starch, glucose, lactose, sucrose, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like.
- the tablets or capsules may be prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (for example pregelatinized corn starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); bulking agents (for example, lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (for example, magnesium stearate, talc or silica); disintegrants (for example, potato starch or sodium starch glycolate); or wetting agents (for example, sodium lauryl sulfate). Tablets can be coated by methods well known in the art.
- pharmaceutically acceptable excipients such as binding agents (for example pregelatinized corn starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); bulking agents (for example, lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (for example, magnesium stearate, talc or silica); disintegrants (for example, potato starch or sodium starch glycolate); or wetting
- Liquid preparations for oral administration may take, for example, the form of solutions, syrups or suspensions, or they may be presented as a dry product to be reconstituted with water or another suitable vehicle before use.
- These liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (for example, sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (for example, lecithin or acacia); non-aqueous vehicles (for example, almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (for example, methyl or propyl-p-hydroxybenzoates or sorbic acid).
- the preparations may also contain buffering salts, flavoring agents, dyes and sweeteners, as appropriate.
- composition according to the invention may also comprise a cell culture medium, preferably a culture medium capable of cultivating human or animal cells.
- the invention also relates to a method for eliminating pathogenic microorganisms present in one or more flatworms, said method comprising a step which consists in feeding one or more flatworms, preferably exclusively, with malted yeast for a time sufficient to eliminate said pathogenic microorganisms.
- the method according to the invention does not require the use of antibiotics in order to have a flatworm free of human-pathogenic microorganisms.
- the method allows in particular to obtain one or more flatworms according to the invention, as defined in the section “Flatworm and composition containing same” above.
- the flatworms are fed at least once a week, preferably at least twice a week, with an amount of malted yeast ranging from 0.10 mg of yeast/400 flatworms to 0.20 mg of yeast/400 flatworms, preferably an amount of 0.15 mg yeast/400 flatworms.
- Flatworms are fed for the time necessary to be free of human-pathogenic microorganisms.
- the flatworms are fed for at least one week, preferably for at least 2 weeks, for example for 4 weeks.
- the flatworms are deprived of all food for at least one week before being fed with the malted yeast.
- the invention also relates to a method for preparing a flatworm extract according to the invention, comprising the steps of:
- Step (b) preparing the extract is described in more detail in the section “Flatworm extract” above.
- the invention also relates to the use of an extract according to the invention or of a composition comprising an extract according to the invention, to cultivate human or animal cells in vitro or ex vivo.
- the invention relates to the use of an extract according to the invention or of a composition comprising an extract according to the invention, for cultivating human or animal cells in vitro or ex vivo, in which said human cells are not human embryonic stem cells requiring the destruction of a human embryo and having the capacity to develop into a human being.
- the extract can for example be used to regenerate human or animal cells, for example by stimulating their differentiation, their growth, their multiplication and/or their proliferation. According to a particular aspect, the extract is used to regenerate human dental stem cells.
- the human or animal cells can be any type of cell, for example stem cells or differentiated cells.
- stem cells considered are human stem cells, the latter are not human embryonic stem cells requiring the destruction of a human embryo and having the capacity to develop into a human being.
- differentiated cells reference may in particular be made to epithelial cells, fibroblasts, keratinocytes, endothelial cells, neuronal cells or nerve cells.
- Another object of the present invention relates to the use of an extract according to the invention or of a composition comprising an extract according to the invention as an anti-aging agent, healing agent and/or agent for regenerating human or animal cells, wherein said extract or said composition is applied topically.
- topical route refers to an application to the skin, the mucous membranes, the superficial body growths such as the nails, body hair and hair, preferably the skin, for example an application to healthy skin.
- the person skilled in the art will be able to determine the amount and frequency of application depending on the anti-ageing, healing and/or regenerating effect sought and the type of cells targeted.
- the anti-ageing, healing and/or regenerating effects can be measured by analyzing the expression of one or more genes whose role in cell ageing, healing or else cell proliferation is known.
- a cosmetic method for treating the skin for example healthy skin, to combat the signs of skin ageing, and in particular the expression wrinkles caused by uncontrolled facial muscle contractions, consisting in applying to the areas of the skin requiring such treatment, a cosmetic composition according to the invention.
- the invention also relates to an extract according to the invention or a composition comprising an extract according to the invention, for the use thereof as a medicament.
- the extract or composition can be formulated for parenteral administration, for example intravascular (intravenous or intra-arterial), intraperitoneal, intramuscular, enteral or topical administration.
- parenteral administration for example intravascular (intravenous or intra-arterial), intraperitoneal, intramuscular, enteral or topical administration.
- the administration or the application can be done at once or, more generally, in several times.
- the duration of treatment may vary depending on the pathology being treated and the subject being treated.
- the extract or the composition can be used in monotherapy or in combination with drugs whose therapeutic interest is recognized in the considered pathology.
- the invention relates to an extract according to the invention or a composition comprising an extract according to the invention, for the use thereof to promote the healing of a skin wound or a skin burn.
- Topical administration is preferred in this indication.
- Example 1 Analysis of the Microorganisms Contained in Planarians Fed with Different Diets
- a first group of 400 planarians ( Schmidtea mediterranea ) was fed twice a week, for 2 weeks, with 0.15 g of malted yeast (Markal—Malt beer yeast—Flakes 250 g), that is to say 0.0375 g/100 planarians/feeding.
- a second group of 400 planarians ( Schmidtea mediterranea ) was fed twice a week, for 2 weeks, with calf liver (SAPRIMEX company, Italy) at 0.40 mg/400 planarian/feeding.
- microorganisms contained in the two groups of planarians were analyzed and identified by analyzing the microbiota according to the protocol detailed below.
- planarians were washed in water sterilized by filtration, then the planarians were inoculated on BCYE agar (Oxoid Kunststoff GmbH, Wesel, Germany), Luria Bertani (LB) or Columbia agar enriched with 5% sheep blood (bioMérieux, Marcy l'étoile, France).
- BCYE agar Oloid GmbH, Wesel, Germany
- Luria Bertani LB
- Columbia agar enriched with 5% sheep blood bioMérieux, Marcy l'étoile, France.
- Each of the inoculations is incubated under three different temperature conditions (19° C., 28° C. and 37° C.) and under two conditions of incubation time (24 h and 48 h), namely 24 h at 19° C., 24 h at 28° C., 24 h at 37° C., 48 h at 19° C., 48 h at 28° C.
- Each individual bacterial colony was harvested and identified by MALDI-TOF-MS (Microflex Spectrometer; Bruker Daltonics, Bremen, Germany). The spectra obtained were imported into the MALDI Biotyper 3.0 software (Bruker Daltonics) and analyzed with respect to the reference spectra of the bacteria included in the database (Bruker database constantly updated with the Mediterranee-Infection database.
- the MALDI Biotyper RTC software was used to interpret the results according to scores obtained: a colony was probably identified at the species for a score >2.0, probably identified for a score between 1.99 and 1.7, but not identified for a score ⁇ 1.7.
- Planarian fed with malted yeast were free of bacteria likely to be pathogenic for humans.
- Planarians fed with malted yeast comprised a single bacterial species, non-pathogenic to humans: Pseudomonas brenneri.
- Urmitella massiliensis, Paenibacillus polymyxa and Micrococcus luteus were found in malted yeast fed to planarians, but these bacteria were not found in planarians after feeding with malted yeast.
- Planarians fed with calf liver contained 11 bacteria likely to be pathogenic for humans (Table 2) and 25 non-pathogenic bacteria (Table 3).
- Dugesia japonica exclusively with malted yeast allowed the elimination of all human-pathogenic bacteria detected when the planarians are fed with calf liver. No pathogenic bacteria for humans have been detected in Dugesia japonica fed exclusively with malted yeast.
- the malted yeast is inactivated by heat treatment at a temperature of 50° C. for 1 hour.
- Planarians belonging to the Schmidtea mediterranea species fed exclusively with inactivated malted yeast contain bacteria that are pathogenic for humans, namely:
- Feeding planarians with inactivated malted yeast does not eliminate the human-pathogenic microorganisms present in Schmidtea mediterranea.
- the material and method of this test is the same as that implemented in example 1 of the patent application but by feeding the planarians exclusively with baker's yeast Saccharomyces cerevisiae and not exclusively with malted yeast ( Saccharomyces cerevisiae +malt according to the invention).
- Planarians belonging to the Schmidtea mediterranea species fed exclusively with baker's yeast contain bacteria that are pathogenic for humans, namely:
- Feeding planarians with baker's yeast does not eliminate the human-pathogenic microorganisms present in Schmidtea mediterranea.
- Example 2 Tests of Different Diets without Element of Animal Origin on Planarians Belonging to the Schmidtea mediterranea Species
- Planarians belonging to the Schmidtea mediterranea species are fed according to the same method as in Example 1 part a) with different foods without element of animal origin.
- the different foods tested are as follows: baker's yeast, spirulina, tofu, soy protein, soy milk, oatmeal or malt.
- Platyhelminthes do not feed in a perennial way with any of these foods without element of animal origin. Surprisingly, flatworms do not accept feeding with malt unlike malted yeast. Feeding flatworms with each of the foods free of elements of animal origin, except malted yeast, does not eliminate the human-pathogenic microorganisms present in Schmidtea mediterranea.
- flatworms do not accept perennial feeding with baker's yeast ( Saccharomyces cerevisiae ) but accept feeding with malted yeast ( Saccharomyces cerevisiae with malt), which differs from baker's yeast only by the presence of malt.
- planarians were washed twice with 200 ml of sterile water (ceramic: microfiltration (0.2 micron), interior of the antibacterial ceramic, compacted activated carbon). The washed planarians were transferred to a tube and the water was removed then the planarians were frozen at ⁇ 80° C.
- the tube containing the frozen planarians was placed on ice until thawed. 20 ml of sterile water (temperature 4° C.) was added to the thawed planarians. 1 cm of sterile glass ball (diameter 3 mm) was added to the tube (tube A).
- Tube A was mixed using a mechanical stirrer for 5 minutes at 2500 cycles/minute.
- the content of tube A was passed through a syringe equipped with a 23 g needle and placed in a new tube (tube B).
- Tube A 20 ml of sterile water (temperature of 4° C.) was added to tube A containing the glass beads and the residues which remained stuck to the beads. Tube A was again mixed using a mechanical stirrer for 5 minutes at 2500 cycles/minute. The content of tube A was again passed through a syringe equipped with a 23 g needle then transferred to tube B. Tube B now contains 40 ml of crude planarian extract.
- Tube B is centrifuged for 5 min at 3220 g at 4° C. then the supernatant of tube B was filtered through a 1.20 ⁇ m membrane (filtrate 1). Filtrate 1 was then filtered on a 0.80 ⁇ m membrane (filtrate 2). Filtrate 2 was then filtered on a 0.45 ⁇ m membrane (filtrate 3). Filtrate 3 was then filtered on a 0.2 ⁇ m membrane (filtrate 4). Filtrate 4 only contained particles smaller than 0.2 ⁇ m.
- the protein concentration of filtrate 4 was determined by absorbance at the wavelength of 280 nm.
- the protein concentration obtained was comprised between 17.5 and 20 mg of protein/mL.
- the filtrate 4 (corresponding to an aqueous extract freed from any insoluble solid debris larger than 0.2 ⁇ m) was freeze-dried and stored at 4° C. for subsequent use.
- Filtrate 4 was analyzed in triplicate by MALDI-TOF according to the protocol detailed below.
- a 1 ⁇ l sample of aqueous extract from example 4A was diluted to 1/20th with a mixture of trichloroacetic acid, acetonitrile and water and was deposited on an HCCA matrix. Then, 1 ⁇ L of HCCA saturated matrix was added on top, then the whole was dried for 10 minutes. The analysis of the extract was performed with a Maldi-Tof Microflex LT10 (Bruker) mass spectrometer. The results were collected with the MALDl Biotype RTC software.
- the parameters applied to the mass spectrometer were as follows: positive linear model Electrode 151 : 20.00 kV, Electrode 152 : 18.05 kV, Focusing electrode: 6 kV1 Laser frequency: 60 Hz, Detector gain: 8.8 ⁇ , Post Ion Extraction (PIE): 120 ns, Mass range: from 700 to 20000 Da.
- BIOTYPER® software from the manufacturer BRUKER DALTONICS® which allows to apply the automatic method described above to a series of samples taking into account the criteria mentioned above and a quality score or validation score which represents the addition of 2 ratings nl+n2 (n1 being a function of the number of peaks and n2 a function of the signal/background noise ratio):
- a spectrum is taken into account if its validation score (nl+n2) is greater than 2.
- Example 4 The cytotoxicity of the aqueous extract obtained in Example 3 (filtrate 4) was tested on HL60 human lymphocyte cells (ATCC CCL-240). The cells were contacted with different dilutions of the extract. Briefly, 5 ⁇ 10 4 cells/well (24-well plate) were cultured in RPMI medium (GibCoBRL) supplemented with fetal calf serum (10%) and penicillin and streptomycin (5000 U/ml, 5000 ⁇ g/ml respectively), at 37° C., and under a 5% CO2 atmosphere.
- RPMI medium GibCoBRL
- penicillin and streptomycin 5000 U/ml, 5000 ⁇ g/ml respectively
- the cells used were human stem cells (ATCC CLS-300702).
- the cells were contacted with different dilutions of the extract. Briefly, 5 ⁇ 10 3 cells/well, on a 48-well plate, were cultured in DMEM/F12 medium (GibCoBRL) supplemented with fetal calf serum (10%) and penicillin and streptomycin (5000 U/ml, 5000 ⁇ g/ml respectively), at 37° C., and under 5% CO2 atmosphere.
- DMEM/F12 medium GibCoBRL
- penicillin and streptomycin 5000 U/ml, 5000 ⁇ g/ml respectively
- FIG. 2 C shows the growth of human stem cells treated with the planarian aqueous extract diluted to 1/20 th for 9 days and the control without treatment. The cells were stained with Giemsa.
- the cells used were human epithelial cells (ATCC CCL-2).
- the cells were contacted with different dilutions of the extract. Briefly, 5 ⁇ 10 3 cells/well, on a 48-well plate, were cultured in DMEM medium (GibCoBRL) supplemented with fetal calf serum (10%) and penicillin and streptomycin (5000 U/ml, 5000 ⁇ g/ml respectively), at 37° C., and under a 5% CO2 atmosphere.
- DMEM medium GibCoBRL
- penicillin and streptomycin 5000 U/ml, 5000 ⁇ g/ml respectively
- FIG. 3 D shows the growth of human epithelial cells treated with the aqueous extract diluted to 1/20 th for 9 days and the control without treatment. The cells were stained with Giemsa.
- the cells used were human endothelial cells (ATCC CRL-1730). The cells were contacted with different dilutions of the extract. Briefly, 5 ⁇ 10 3 cells/well, on a 48-well plate, were cultured in DMEM medium (GibCoBRL) supplemented with fetal calf serum (10%) and penicillin and streptomycin (5000 U/ml, 5000 ⁇ g/ml respectively), at 37° C., and under a 5% CO2 atmosphere.
- DMEM medium GibCoBRL
- penicillin and streptomycin 5000 U/ml, 5000 ⁇ g/ml respectively
- FIG. 4 B A dilution (1/20; FIG. 4 B ), ranging from 1:5 ( FIG. 4 A ) to 1:100 ( FIG. 4 C ), allowed a significant induction (*p ⁇ 0.05) of the proliferation of human endothelial cells compared to untreated cells.
- the induction of multiplication was about 1.38 times.
- Example 4 A 1/20 dilution of the planarian aqueous extract obtained in Example 3 (filtrate 4) treated at 95° C. for 10 minutes is added to the human cells of interest. Cell multiplication was measured after 9 days.
- the heat-inactivated planarian aqueous extract does not induce cell multiplication.
- planarian aqueous extract induced healing genes, immune genes, cell renewal genes, cell migration genes, genes for protection against photo-aging, anti cell death genes, and hyaluronic acid receptor activating genes.
- FIG. 1 illustrates the measurement of the cytotoxicity of the planarian aqueous extract on human lymphocyte cells.
- FIGS. 2 A to 2 D illustrate the measurement of the planarian aqueous extract on the multiplication of human stem cells. Only a dilution comprised (1/20, B) between 1/5 (A) and 1/100 (C) allows a significant induction (*p ⁇ 0.05) of the proliferation of human stem cells compared to untreated cells.
- FIG. 2 D shows the growth of human stem cells treated with the planarian aqueous extract diluted to 1/20 for 9 days and the control without treatment. The cells are stained with Giemsa.
- FIGS. 3 A to 3 D illustrate the measurement of the effect of the planarian aqueous extract on the multiplication of human epithelial cells.
- the cells used are human epithelial cells (ATCC CCL-2).
- a dilution (1/20; B) and 1:5 (A) and 1:100 (C) allows a significant induction (*p ⁇ 0.05) of the proliferation of human epithelial cells compared to untreated cells.
- FIG. 3 D shows the growth of human epithelial cells treated with the planarian aqueous extract diluted to 1/20 for 9 days and the control without treatment. The cells are stained with Giemsa.
- FIGS. 4 A to 4 C illustrate the measurement of the effect of the planarian aqueous extract on the proliferation of human endothelial cells.
- the cells used are human endothelial cells (ATCC CRL-1730).
- a dilution (1/20; B) and 1:5 (A) and 1:100 (C) allows a significant induction (*p ⁇ 0.05) of the proliferation of human endothelial cells compared to untreated cells.
- FIGS. 5 A to 5 C illustrate the measurement of the effect of the aqueous extract of heat-treated planarian on the replication of human stem cells (ATCC CLS-300702), human endothelial cells (ATCC CRL-1730), human epithelial cells (ATCC CCL-2).
- a 1/20 dilution of the planarian aqueous extract is treated at 95° C. for 10 minutes is added to the human cells of interest and the multiplication of the cells is measured after 9 days.
- the heat inactivates the activity of the planarian aqueous extract since no cell proliferation is observed either for human stem cells (A), human epithelial cells (B), or human endothelial cells (C).
- the aqueous heat-inactivated planarian extract does not induce cell multiplication.
- FIGS. 6 A and 6 B illustrate the measurement of the effect of the planarian aqueous extract on the healing of a cellular layer of human stem cells and human epithelial cells.
- the human cells of interest are cultured to confluence until a cellular layer is formed.
- a 325 ⁇ m wide lesion of the cellular layer is made using a calibrated needle, then the planarian aqueous extract diluted to 1/20 th is added or not to the cell culture.
- Healing of the cellular layer complete filling of the lesion with new cells is monitored over time.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Environmental Sciences (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
- The present invention relates to a method for feeding a flatworm and to a flatworm extract that is free of human-pathogenic microorganisms, useful in the pharmaceutical, cosmetic and nutraceutical fields.
- The term “flatworms” designates a phylum of tapeworms which includes four classes: the rhabditophora (formerly “turbellarians”) such as the planarian, the monogeneans which are parasites of aquatic organisms, the trematodes (flukes, digeneans) which are parasites such as liver fluke, and cestodes such as tape worm or taenia.
- Planarians are aquatic tapeworms belonging to several species in the class of Rhabditophora. They can be swimmers or crawlers, and live at sea, in fresh water, or in very humid soils (in tropical forests). Planarians are known for their regenerative abilities. They are able to perpetually regenerate themselves, and any part of their body, due to the presence of a large amount of stem cells (20-30%) in their tissues compared to other living organisms for which the amount of stem cells is of the order of 1 ppm. Planarian stem cells multiply and regenerate continuously, unlike the stem cells of more evolved organisms, which multiply little or not at all. The biochemical factors allowing the multiplication of stem cells in a planarian remain unidentified.
- Flatworms are known to feed on substances of animal origin in their natural environment, and are generally fed with calf liver or chicken liver when reared in the laboratory. Because of their diet, flatworms harbor human-pathogenic microorganisms in their microbiota.
- Flatworm extracts are described in the literature as having numerous pharmacological properties.
- Patent application WO2019016346 describes a planarian aqueous extract, which is non-parasitic and non-pathogenic in humans, in particular of the Schmidtea mediterranea species, capable of activating the multiplication of human stem cells and which therefore has a cell regeneration activity useful in numerous cosmetic, pharmaceutical or nutraceutical applications.
- The flatworms used to obtain flatworm extracts are generally fed with calf liver. However, the analysis of their microbiota revealed the presence of human-pathogenic microorganisms, such as Aeromonas veronii, Staphylococcus capitis, Pseudomonas fluorescens, Acinetobacter guillouiae, Aeromonas hydrophila, Delftia acidovorans, Comamonas testosteroni, Sphingomonas paucimobilis, Staphylococcus epidermidis, Micrococcus luteus and/or Staphylococcus haemolyticus.
- These microorganisms can be problematic in all cosmetic, pharmaceutical or nutraceutical applications resulting from the use of flatworm extracts or flatworms as such.
- In the context of the present invention, it has been observed that it was very difficult to be able to sustainably feed flatworms with a food free of element of animal origin. Fortuitously, the Applicant was able to observe that flatworms agree to feed with malted yeast, which is a food free of any element of animal origin.
- In the context of the present invention, it has also been shown quite fortuitously that it was possible to have flatworms free of human-pathogenic microorganisms by feeding said flatworms with malted yeast. The extracts obtained from these “healthy” flatworms retain the ability to activate the multiplication of human stem cells and therefore have a cell regeneration activity, in particular stem or differentiated cells.
- A first object of the present invention relates to a method for feeding flatworms, in which the flatworms are fed exclusively with malted yeast.
- A second object of the present invention relates to a method for preparing a flatworm extract, comprising the steps of:
-
- (i) feeding flatworms by implementing the feeding method according to the first object of the invention, and
- (ii) preparing a flatworm extract from the flatworms obtained in step (i).
- A third object of the present invention relates to a flatworm extract fed exclusively with malted yeast capable of being obtained by implementing the method according to the second object of the invention, said flatworms being free of human-pathogenic microorganisms.
- A fourth object of the present invention relates to a composition comprising one or more flatworms fed exclusively with malted yeast, said flatworm(s) being free of human-pathogenic microorganisms.
- A fifth object of the present invention relates to a composition comprising an extract according to the invention.
- A sixth object of the present invention relates to a method for eliminating pathogenic microorganisms present in one or more flatworms, said method comprising a step which consists in feeding one or more flatworms, preferably exclusively, with malted yeast for a sufficient period to eliminate said pathogenic microorganisms.
- A seventh object of the present invention relates to a method for preparing a flatworm extract according to the invention, comprising the steps of: (a) obtaining flatworms free of human-pathogenic microorganisms by implementing the method for eliminating pathogenic microorganisms from flatworms according to the invention; (b) preparing a flatworm extract from the flatworms obtained in step (a).
- An eighth object of the present invention relates to the use of an aqueous extract according to the invention or of a composition comprising an extract according to the invention, for cultivating human or animal cells in vitro or ex vivo.
- A ninth object of the present invention relates to an extract according to the invention or a composition comprising an extract according to the invention, for the use thereof as a medicament, for example to be used to promote the healing of a wound in the skin or a skin burn.
- The term “flatworm” refers to a flatworm from the phylum of the same name. In the context of the invention, the flatworm can be of the class of rhabditophora, preferably it is a planarian. Preferably, the flatworm according to the invention is non-parasitic and/or non-pathogenic in humans. Advantageously, the flatworm according to the invention is a planarian belonging to one of the following species Schmidtea mediterranea, Dugesia japonica, Dendricoelum lacteum, Polycelis nigra, Polycelys tenuis and planarian torva, preferably to Schmidtea mediterranea species.
- “Malted yeast” or “brewer's yeast” is well described in the literature, it is the result of growing Saccharomyces cerevisiae with malt, usually barley malt. It usually comes in the form of flakes and is widely used in vegetarian diets. The malted yeast according to the present invention can be in any form suitable for feeding flatworms, for example in the form of powder, flakes, granules or in liquid form, for example obtained by mixing flakes with water. The yeasts present in the malted yeast are said to be “active”, that is to say they are alive.
- The expression “flatworm free of human-pathogenic microorganisms” designates a flatworm whose digestive tract is free of human-pathogenic microorganisms, that is to say a flatworm whose microbiota is free of human-pathogenic microorganisms. In a particular embodiment, the human-pathogenic microorganisms are Aeromonas veronii, Staphylococcus capitis, Pseudomonas fluorescens, Acinetobacter guillouiae, Aeromonas hydrophila, Delftia acidovorans, Comamonas testosteroni, Sphingomonas paucimobilis, Staphylococcus epidermidis, Micrococcus luteus and Staphylococcus haemolyticus. In this particular embodiment, the microbiota of the flatworm of the invention is therefore free of the set of pathogenic microorganisms mentioned above.
- The term “extract” designates the product resulting from the extraction of the contents of the cells. Thus, the term “extract of one or more flatworms” designates the product resulting from the extraction of the contents of the cells of said flatworm(s).
- The term “pharmaceutically acceptable” means approved by a federal or state regulatory agency or listed in the United States or European Pharmacopoeia, or other generally recognized pharmacopoeia, for use in animals and humans. A “pharmaceutical composition” means a composition comprising a pharmaceutically acceptable vehicle. For example, a pharmaceutically acceptable vehicle can be a diluent, adjuvant, excipient, or vehicle with which the therapeutic agent is administered. These vehicles can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. Saline solutions and aqueous solutions of dextrose and glycerol can also be used as liquid vehicles, especially for injection solutions. Pharmaceutically acceptable excipients comprise starch, glucose, lactose, sucrose, sodium stearate, glycerol monostearate, talc, sodium chloride, skimmed milk powder, glycerol, propylene glycol, water, ethanol and the like. When the pharmaceutical composition is suitable for oral administration, the tablets or capsules can be prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (for example pregelatinized corn starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (for example lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (for example, magnesium stearate, talc or silica); disintegrants (for example potato starch or sodium starch glycolate); or wetting agents (for example, sodium lauryl sulfate). The tablets can be coated by methods well known in the state of the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or may be presented as a dry product to be reconstituted with water or another suitable vehicle before use. Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable vehicles such as suspending agents (for example sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (for example, lecithin or acacia); non-aqueous vehicles (for example almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (for example methyl or propyl p-hydroxybenzoates or sorbic acid). The pharmaceutical compositions may also contain buffering salts, flavoring agents, dyes and sweeteners, as appropriate.
- The term “treating” or “treatment” encompasses any beneficial or desirable effect on a pathology or pathological condition, and may even include minimal reduction of one or more measurable markers of the pathology or pathological condition. The treatment may, for example, involve either reducing or improving the symptoms of the pathology or pathological condition, or delaying the progression of the pathology or pathological condition. The term “treatment” does not necessarily mean the complete eradication or cure of the pathology, nor of the associated symptoms.
- Flatworm and Composition Containing Same
- The description relates to a flatworm fed exclusively with malted yeast, said flatworm being free of human-pathogenic microorganisms.
- The inventors realized that flatworms fed exclusively with malted yeast were free of human-pathogenic microorganisms, whereas flatworms fed with conventional food, such as calf liver, or even fed with baker's yeast (Saccharomyces cerevisiae), develop human-pathogenic microorganisms in their digestive tract.
- The inventors have therefore shown that it suffices to feed flatworms exclusively with malted yeast to obtain flatworms free of human-pathogenic microorganisms.
- Thus, the present invention does not require the use of antibiotics to obtain flatworms free of human-pathogenic microorganisms. The flatworms of the present description are therefore not only free of human-pathogenic microorganisms, but also free of antibiotics.
- Flatworms can be alive or dead. It can for example be frozen, freeze-dried and/or dried.
- According to the present description, the flatworm is advantageously free of the following human-pathogenic microorganisms: Aeromonas veronii, Staphylococcus capitis, Pseudomonas fluorescens, Acinetobacter guillouiae, Aeromonas hydrophila, Delftia acidovorans, Comamonas testosteroni, Sphingomonas paucimobilis, Staphylococcus epidermidis, Micrococcus luteus and Staphylococcus haemolyticus.
- The invention also relates to a composition comprising one or more flatworms fed exclusively with malted yeast, said flatworm(s) being free of human-pathogenic microorganisms.
- It may be, for example, a composition comprising the flatworm(s) in their environment, for example a composition comprising water, at least one flatworm according to the invention and optionally malted yeast. It may for example be a composition comprising one or more flatworms according to the present description and exclusively malted yeast as food for the flatworm(s).
- The composition can be in various forms, for example in liquid form or in freeze-dried form. In freeze-dried form, the composition may additionally comprise a lyoprotectant, such as an unnatural lyoprotectant.
- Method for Feeding Flatworms and Method for Preparing a Flatworm Extract
- An object of the present invention relates to a method for feeding flatworms, in which the flatworms are fed exclusively with malted yeast.
- The inventors have observed that it is very difficult to be able to sustainably feed flatworms with a food free of any element of animal origin. Indeed, flatworms refuse to feed with the majority of foods free of elements of animal origin.
- For example, the inventors tested the following foods: baker's yeast, spirulina, soy protein, soy milk, tofu, oatmeal, malt and none of these foods was accepted as perennial food by flatworms. Consequently, these foods do not allow to obtain one or more flatworms free of element of animal origin.
- In addition, these foods had no impact on the flatworm microbiota and in particular on the population of human-pathogenic bacteria.
- Surprisingly, while flatworms refuse to feed on a long-term basis with malt or baker's yeast (Saccharomyces cerevisiae), the Applicant has demonstrated that flatworms accept to feed on a long-term basis with malted yeast (Saccharomyces cerevisiae with malt). Flatworms agree to feed exclusively with malted yeast, which advantageously allows to obtain flatworms not only free of human-pathogenic microorganisms but also free of element of animal origin.
- The feeding method according to the invention comprises a step which consists in feeding the flatworms for a sufficient time to eliminate the human-pathogenic microorganisms and/or eliminate the elements of animal origin.
- In a particular embodiment, the flatworms are fed at least once a week, preferably at least twice a week, with an amount of malted yeast ranging from 0.10 mg of yeast/400 flatworms to 0.20 mg of yeast/400 flatworms, preferably an amount of 0.15 mg yeast/400 flatworms.
- Flatworms are fed for the time necessary to be free of human-pathogenic microorganisms. In a particular embodiment, the flatworms are fed for at least one week, preferably for at least 2 weeks, for example for 4 weeks.
- Advantageously, the flatworms are deprived of all food for at least one week before being fed with the malted yeast.
- Another object of the present invention relates to a method for preparing a flatworm extract, comprising the steps of:
-
- (i) feeding flatworms by implementing the feeding method according to the invention, and
- (ii) preparing a flatworm extract from the flatworms obtained in step (i).
- Step (ii) of preparing the extract is described in more detail in the “flatworm extract” section below.
- Flatworm Extract
- Another object of the invention relates to a flatworm extract fed exclusively with malted yeast which can be obtained by implementing the method for preparing a flatworm extract according to the invention, said flatworms being free of human-pathogen microorganisms.
- The extract according to the invention can for example be an aqueous extract.
- Since flatworms are fed exclusively with malted yeast, the extract according to the invention is free of antibiotics. The absence of antibiotic within the extract according to the invention makes it particularly suitable for use in humans or animals. In addition, the extract according to the invention is free of elements of animal origin other than those relating to the flatworm itself. This advantageously allows to have an extract that is particularly suitable for use in vegan products, that is to say products not comprising any ingredient of animal origin, such as vegan cosmetic products.
- The preparation of a flatworm extract does not have any particular difficulty, numerous extraction methods being described in the literature. The preparation of a flatworm extract is not limited to a particular method, and the conventional methods can be implemented to prepare an extract according to the invention, such as for example by implementing a method comprising the following steps: (i) grinding flatworms in order to obtain a ground material, (ii) ridding the ground material of insoluble solid debris in order to obtain an extract, and (iii) optionally concentrating or diluting the extract.
- Step (i) can be implemented with any grinding method allowing to burst the flatworm cells and to release their contents, for example by shaking flatworms with glass beads.
- Step (ii) can be implemented by centrifuging and/or filtering the ground material. Advantageously, the extract according to the invention is cleared of any insoluble solid debris, in particular cleared of membrane debris resulting from the bursting of flatworm cells. To obtain such an extract, the preparation method may comprise at least one solid/liquid separation step, for example one or more membrane filtration steps having an appropriate cut-off threshold, for example a cut-off threshold of 1.20 μm, for example 0.80 μm, 0.45 μm, 0.2 μm. Filtration allows to obtain an extract which contains particles of a size less than the cut-off threshold of the filter used, for example particles of a size of less than 1.20 μm, for example less than 0.80 μm, less than 0.45, less than μm 0.2 μm.
- Step (iii) can be implemented by evaporation or by adding a suitable solvent, for example water.
- Example 3 describes a method for preparing a flatworm extract according to the invention.
- The extraction conditions will be chosen such that the extract obtained has the desired concentration in the intended application. The protein concentration of the crude extract can vary in particular depending on the amount of flatworm used (for example, during an aqueous extraction, when the ratio flatworm/water is increased, the protein concentration of the extract also increases), the extraction time (for example, an increase in the extraction time during an aqueous extraction generally allows to increase the protein concentration of the extract) and/or the extraction temperature (for example, an increase in the extraction temperature during an aqueous extraction generally allows to increase the protein concentration of the extract). Generally, the crude extract comprises from 1 mg to 50 mg of proteins per mL of extract (mg/mL). The absorbance at the characteristic wavelength of 280 nm (that is to say A280 nm) is commonly used to estimate the total protein concentration in the extract.
- The extract obtained can be more or less concentrated in proteins depending on the intended use. After extraction, the extract may in particular comprise between 15 mg of protein per mL of extract (mg/mL) and 20 mg/mL. The crude extract can be diluted or even concentrated depending on the intended use. In a particular embodiment, the extract according to the invention comprises from 15 μg of protein per mL of extract (μg/mL) to 50 mg of protein per mL of extract (mg/mL), for example from 15 μg/mL to 20 mg/L, for example from 15 μg/mL to 1 mg/L, for example from 15 μg/mL to 0.3 mg/L. In another particular embodiment, the extract according to the invention comprises less than 0.5 mg of protein per mL of extract (mg/mL), for example less than 0.3 mg/mL, for example between 15 μg/mL and 0.3 mg/mL, preferably 15 μg mg/mL to 75 μg/mL. Complete dehydration of this extract allows to obtain an extract in powder form.
- In a very particular embodiment, the extract according to the invention has a MALDI TOF spectrum corresponding to the data shown in Table 1.
-
TABLE 1 Extract 1Extract 2 Extract 3 m/z Intensity S/N m/z Intensity S/N m/z Intensity. S/N 2001 5051 8 2000.7 5566 8 2001.2 1706 7 2390.4 3699 5 2723.3 3988 7 2723.8 2062 9 2723.7 4012 8 3335.8 3074 5 3335.7 1224 5 3335.6 2812 5 3672.7 3390 7 3673.2 2021 9 3673.3 3533 9 3708.1 4153 10 3708.4 2804 13 3708.7 4596 13 4551.1 2822 7 3760.5 1500 7 3760.9 2701 6 4871.2 3613 10 4550.7 1414 7 4551.4 2604 7 5012.3 2930 8 4871.1 2254 11 4871.6 3185 10 5072.5 3321 9 5012.6 1683 9 5012.9 2746 8 5267.7 2351 6 5060 974 5 5060.4 2042 5 5646.8 7211 28 5072.8 2096 11 5072.8 3282 10 5870.1 2197 6 5268 1410 7 5268.3 2221 6 5890.7 2105 6 5647.1 5163 30 5647.6 6601 28 5906.5 2005 6 5870.4 1070 6 5871.3 1808 5 6393.6 5383 23 5890.8 1067 6 5891.4 1859 6 6415.4 1900 6 5906.7 1008 6 5907.7 1886 6 6432.8 4926 20 5965 901 5 5965.5 2019 6 6487 2204 7 6393.6 3673 24 6394.2 4603 21 6534.1 3192 12 6414.6 882 6 6433.5 4207 19 6556.8 4018 16 6433.2 3106 20 6487.8 2003 7 6577.9 1864 6 6487.1 1245 8 6535 2888 12 6674.1 5905 27 6534.4 1980 13 6557.6 3510 15 6695.2 1817 6 6557 2491 16 6675.2 4693 23 7347.6 7866 44 6674.5 3967 28 7306.6 1498 5 7369.5 2976 14 7348 6232 50 7349 7585 45 7418 10220 58 7369.7 2025 16 7369.9 2881 15 7438.6 3214 15 7418.4 7822 62 7419.5 8974 54 7471.5 2704 12 7472 1966 16 7472.7 2731 14 7492.2 2184 9 7523 4434 37 7524.1 5714 35 7522.9 5581 31 7542.1 1296 11 7568 1726 7 7541.6 2177 10 7569.3 1048 9 7588.1 3819 22 7564.9 1721 7 7587.1 2747 23 7606.4 1577 6 7586.4 3623 19 7754.2 616 5 7755.1 1452 6 7607 1645 6 8470.5 1655 17 8471.3 2189 15 8469.5 2390 16 8498.9 806 8 8499.6 1422 8 8498.3 1731 11 8525.6 870 9 8526.7 1394 8 8523.9 1798 11 8545.9 642 7 8547 1154 6 8544.4 1268 7 9395.7 741 9 9396.7 1148 9 9395.2 1143 8 14027.7 146 6 14031.1 223 5 M/z: ratios (mass in Dalton/charge) on the abscissa of the different characteristic peaks of the spectrum; S/N: ratios (peak intensity/background noise intensity) of the different characteristic peaks of the spectrum. - Composition Comprising a Flatworm Extract
- The invention also relates to a composition comprising an extract according to the invention.
- In a first particular embodiment, the composition is a cosmetic and/or dermatological composition and may comprise one or more carriers and/or excipients suitable for the targeted use. In this embodiment, the composition can be in the form of a gel, lotion, cream, ointment, paste or soap. Thus, the composition according to the invention may comprise various usual excipients suitable for external topical administration, in particular excipients that are dermatologically and/or cosmetologically acceptable. These excipients suitable for the formulation are well known to the person skilled in the art and comprise, for example, agents promoting penetration at the skin, moisturizing agents, thickening agents, stabilizing agents, emollient agents and surfactants, emulsifying agents, preservatives, pH adjusting agents, etc. For example, the composition according to the invention is formulated in the form of a cream comprising the extract of the invention and at least the following excipients: an emulsifying agent, an emollient agent, a thickening agent, a moisturizing agent and optionally a preservative. In another example, the composition according to the invention is formulated in the form of a cream comprising the extract of the invention and at least the following additional excipients: a gelling agent, a thickening agent, a moisturizing agent and optionally a preservative. In this first embodiment, the composition according to the invention may also comprise other compounds suitable for cosmetic and/or dermatological use, such as radical scavengers, antioxidant vitamins such as vitamin E, vitamin C, antioxidant agents such as natural polyphenols, enzymes, plant active ingredients, natural anti-inflammatory substances, alcohols, polyols, esters, electrolytes, polar and non-polar oils, polymers, copolymers, phospholipids, dyes, perfumes and/or skin peeling agents.
- In a second particular embodiment, the composition is a nutraceutical composition (or food supplement) and may comprise one or more carriers and/or excipients suitable for the targeted use. In this embodiment, the composition must therefore be able to be ingested. It can be in different dosage forms, such as a dispersion, a capsule, a cachet, a powder, a tablet, etc. The nutraceutical composition can also be in the form of a food, such as a yoghurt, a cereal bar, a gel, a candy, a chewing gum, etc.
- In a third particular embodiment, the composition is a pharmaceutical composition and may comprise a pharmaceutically acceptable vehicle. Pharmaceutically acceptable excipients comprise starch, glucose, lactose, sucrose, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like. When the pharmaceutical composition is suitable for oral administration, the tablets or capsules may be prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (for example pregelatinized corn starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); bulking agents (for example, lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (for example, magnesium stearate, talc or silica); disintegrants (for example, potato starch or sodium starch glycolate); or wetting agents (for example, sodium lauryl sulfate). Tablets can be coated by methods well known in the art. Liquid preparations for oral administration may take, for example, the form of solutions, syrups or suspensions, or they may be presented as a dry product to be reconstituted with water or another suitable vehicle before use. These liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (for example, sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (for example, lecithin or acacia); non-aqueous vehicles (for example, almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (for example, methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffering salts, flavoring agents, dyes and sweeteners, as appropriate.
- The composition according to the invention may also comprise a cell culture medium, preferably a culture medium capable of cultivating human or animal cells.
- Method for Eliminating Pathogenic Microorganisms Present in a Flatworm
- The invention also relates to a method for eliminating pathogenic microorganisms present in one or more flatworms, said method comprising a step which consists in feeding one or more flatworms, preferably exclusively, with malted yeast for a time sufficient to eliminate said pathogenic microorganisms. Advantageously, the method according to the invention does not require the use of antibiotics in order to have a flatworm free of human-pathogenic microorganisms.
- The method allows in particular to obtain one or more flatworms according to the invention, as defined in the section “Flatworm and composition containing same” above.
- In a particular embodiment, the flatworms are fed at least once a week, preferably at least twice a week, with an amount of malted yeast ranging from 0.10 mg of yeast/400 flatworms to 0.20 mg of yeast/400 flatworms, preferably an amount of 0.15 mg yeast/400 flatworms.
- Flatworms are fed for the time necessary to be free of human-pathogenic microorganisms. In a particular embodiment, the flatworms are fed for at least one week, preferably for at least 2 weeks, for example for 4 weeks.
- Advantageously, the flatworms are deprived of all food for at least one week before being fed with the malted yeast.
- Method for Preparing a Flatworm Extract
- The invention also relates to a method for preparing a flatworm extract according to the invention, comprising the steps of:
-
- (a) obtaining flatworms free of human-pathogenic microorganisms by implementing the method for eliminating pathogenic microorganisms present in one or more flatworms according to the invention;
- (b) preparing a flatworm extract from the flatworms obtained in step (a).
- Step (b) preparing the extract is described in more detail in the section “Flatworm extract” above.
- Non-Therapeutic Indications
- The invention also relates to the use of an extract according to the invention or of a composition comprising an extract according to the invention, to cultivate human or animal cells in vitro or ex vivo. In particular, the invention relates to the use of an extract according to the invention or of a composition comprising an extract according to the invention, for cultivating human or animal cells in vitro or ex vivo, in which said human cells are not human embryonic stem cells requiring the destruction of a human embryo and having the capacity to develop into a human being.
- The extract can for example be used to regenerate human or animal cells, for example by stimulating their differentiation, their growth, their multiplication and/or their proliferation. According to a particular aspect, the extract is used to regenerate human dental stem cells.
- The human or animal cells can be any type of cell, for example stem cells or differentiated cells. When the stem cells considered are human stem cells, the latter are not human embryonic stem cells requiring the destruction of a human embryo and having the capacity to develop into a human being.
- Among the differentiated cells, reference may in particular be made to epithelial cells, fibroblasts, keratinocytes, endothelial cells, neuronal cells or nerve cells.
- Another object of the present invention relates to the use of an extract according to the invention or of a composition comprising an extract according to the invention as an anti-aging agent, healing agent and/or agent for regenerating human or animal cells, wherein said extract or said composition is applied topically. The term “topical route” refers to an application to the skin, the mucous membranes, the superficial body growths such as the nails, body hair and hair, preferably the skin, for example an application to healthy skin.
- The person skilled in the art will be able to determine the amount and frequency of application depending on the anti-ageing, healing and/or regenerating effect sought and the type of cells targeted. The anti-ageing, healing and/or regenerating effects can be measured by analyzing the expression of one or more genes whose role in cell ageing, healing or else cell proliferation is known.
- It is also possible to describe here a cosmetic method for treating the skin, for example healthy skin, to combat the signs of skin ageing, and in particular the expression wrinkles caused by uncontrolled facial muscle contractions, consisting in applying to the areas of the skin requiring such treatment, a cosmetic composition according to the invention.
- Therapeutic Indications
- The invention also relates to an extract according to the invention or a composition comprising an extract according to the invention, for the use thereof as a medicament.
- The extract or composition can be formulated for parenteral administration, for example intravascular (intravenous or intra-arterial), intraperitoneal, intramuscular, enteral or topical administration.
- The administration or the application can be done at once or, more generally, in several times. The duration of treatment may vary depending on the pathology being treated and the subject being treated.
- The extract or the composition can be used in monotherapy or in combination with drugs whose therapeutic interest is recognized in the considered pathology.
- In particular, the invention relates to an extract according to the invention or a composition comprising an extract according to the invention, for the use thereof to promote the healing of a skin wound or a skin burn. Topical administration is preferred in this indication.
- a) Planarians Belonging to the Schmidtea mediterranea Species Fed with Calf Liver or Malted Yeast
- A first group of 400 planarians (Schmidtea mediterranea) was fed twice a week, for 2 weeks, with 0.15 g of malted yeast (Markal—Malt beer yeast—Flakes 250 g), that is to say 0.0375 g/100 planarians/feeding.
- A second group of 400 planarians (Schmidtea mediterranea) was fed twice a week, for 2 weeks, with calf liver (SAPRIMEX company, Italy) at 0.40 mg/400 planarian/feeding.
- The microorganisms contained in the two groups of planarians were analyzed and identified by analyzing the microbiota according to the protocol detailed below.
- Microbiota Analysis Protocol
- After two weeks of starvation, the planarians were washed in water sterilized by filtration, then the planarians were inoculated on BCYE agar (Oxoid Deutschland GmbH, Wesel, Germany), Luria Bertani (LB) or Columbia agar enriched with 5% sheep blood (bioMérieux, Marcy l'étoile, France). Each of the inoculations is incubated under three different temperature conditions (19° C., 28° C. and 37° C.) and under two conditions of incubation time (24 h and 48 h), namely 24 h at 19° C., 24 h at 28° C., 24 h at 37° C., 48 h at 19° C., 48 h at 28° C. or 48 h at 37° C. Each individual bacterial colony was harvested and identified by MALDI-TOF-MS (Microflex Spectrometer; Bruker Daltonics, Bremen, Germany). The spectra obtained were imported into the MALDI Biotyper 3.0 software (Bruker Daltonics) and analyzed with respect to the reference spectra of the bacteria included in the database (Bruker database constantly updated with the Mediterranee-Infection database. The MALDI Biotyper RTC software was used to interpret the results according to scores obtained: a colony was probably identified at the species for a score >2.0, probably identified for a score between 1.99 and 1.7, but not identified for a score <1.7.
- Bacterial colonies that were identified using MALDI-TOF, but which were not known in the Bruker database, were identified by phylogenetic analysis, using 16S rRNA sequencing. Genomic DNA was extracted using an EZ1 automaton and the DNA tissue kit (Qiagen, Hilden, Germany). Full amplification and sequencing of the 16S rRNA gene was performed using eight primers on an ABI Prism 3130xl Genetic Analyzer capillary sequencer (Applied Bio systems, Bedford, MA, USA). CodonCode Aligner software was used for sequence alignment, assembly and correction (https://www.codoncode.com/). For taxonomic assignment, a BLASTn search was performed on database nr. A sequence similarity threshold of 98.65% compared to the phylogenetically closest species with the position in the nomenclature was used to delineate a new species. Phylogenetic relationships were deduced from 16S rRNA sequence comparison using MEGA7 software.
- Results of the Microbiota Analysis
- Planarian fed with malted yeast were free of bacteria likely to be pathogenic for humans. Planarians fed with malted yeast comprised a single bacterial species, non-pathogenic to humans: Pseudomonas brenneri.
- It is interesting to note that (non-pathogenic) bacteria Urmitella massiliensis, Paenibacillus polymyxa and Micrococcus luteus were found in malted yeast fed to planarians, but these bacteria were not found in planarians after feeding with malted yeast.
- Planarians fed with calf liver contained 11 bacteria likely to be pathogenic for humans (Table 2) and 25 non-pathogenic bacteria (Table 3).
-
TABLE 2 Pathogenic bacteria found in planarians fed with calf liver Aeromonas veroni Staphylococcus capitis Pseudomonas fluorescens Acinetobacter guillouiae Aeromonas hydrophila Delftia acidovorans Comamonas testosteroni Sphingomonas paucimobilis Staphylococcus epidermidis Micrococcus luteus Staphylococcus haemolyticus -
TABLE 3 Non-pathogenic bacteria found in planarians fed with calf liver Pedobacter ghigonii Marseille-Q2390 (*) Pseudomonas schmidteae Marseille-Q1929 (*) Pseudomonas timonensis Marseille-P9894 Pseudomonas timonensis Marseille-P9899 Chryseobacterium schmidteae Marseille-P9602 (*) Bacillus schmidteae Marseille-P9898 Janthinobacterium timonensis Marseille-P9896 Vogesella uthrealis Pedobacter schmidteae EG (*) Comamonas aquatilis (*) Pedobacter wanjuense Pseudomonas brenneri Variovorax paradoxus Pseudomonas anguilliseptica Chryseobacterium balustine Chryseobacterium scophthalmum Agrobacterium tumefaciens Microbacterium oxydans Micrococcus yunnanensis flavobacterium oncorhynchi flavobacterium tructae Pseudomonas gessardii shinella zoogloeoides Acinetobacter bereziniae ensifer adhaerens Rhizobium giardinii Corynebacterium lipophiloflavum Acidovorax wautersii Sphingomonas bisphenolicum Sphingomonas ginsenosidimutans (*) Newly identified bacteria - It should be noted that the non-pathogenic bacteria Brochothrix thermosphacta, Lactococcus piscium, Pseudomonas frederiksbergensis, Pseudomonas gessardii, Serratia proteamaculans, Staphylococcus hominis, and Pseudomonas azotoformans have been found in calf liver given to planarians, but these bacteria were not found in planarians after feeding with calf liver.
- Conclusion: feeding the planarians with malted yeast allowed to eliminate the microorganisms likely to be pathogenic for humans, and therefore to obtain planarians free of human-pathogenic microorganisms. These planarians free of human-pathogenic microorganisms are particularly suitable for the preparation of a planarian extract which does not have a risk for humans.
- b) Planarians Belonging to the Dugesia japonica Species Fed with Calf Liver or Malted Yeast
- 1) Material and Method
- The material and method of this test is identical to that implemented in example 1 of the patent application with planarians belonging to the Schmidtea mediterranea species but with planarians belonging to the Dugesia japonica species.
- 2) Results of the Microbiota Analysis
- Planarians fed with calf liver contained 9 bacteria pathogenic for humans (Table 4 reproduced below).
-
TABLE 4 Human-pathogenic bacteria found in planarians fed with calf liver Aeromonas veroni Staphylococcus capitis Pseudomonas fluorescens Acinetobacter guillouiae Aeromonas hydrophila Delftia acidovorans Comamonas testosteroni Staphylococcus epidermidis Staphylococcus haemolyticus - Feeding Dugesia japonica exclusively with malted yeast allowed the elimination of all human-pathogenic bacteria detected when the planarians are fed with calf liver. No pathogenic bacteria for humans have been detected in Dugesia japonica fed exclusively with malted yeast.
- 3) Conclusion
- Feeding Dugesia japonica planarians exclusively with malted yeast has eliminated human-pathogenic microorganisms. These planarians free of human-pathogenic microorganisms are particularly suitable for the preparation of a planarian extract which does not have a risk for humans.
- c) Planarians Belonging to the Schmidtea mediterranea Species Fed with Heat-Inactivated Malted Yeast
- 1) Material and Method
- The material and method of this test is the same as that implemented in example 1 of the patent application but by feeding the planarians exclusively with inactivated malted yeast and not exclusively with live malted yeast.
- The malted yeast is inactivated by heat treatment at a temperature of 50° C. for 1 hour.
- 2) Results of the Microbiota Analysis
- Planarians belonging to the Schmidtea mediterranea species fed exclusively with inactivated malted yeast contain bacteria that are pathogenic for humans, namely:
-
TABLE 5 Human-pathogenic bacteria found in planarians fed with inactivated malted yeast Aeromonas veroni Staphylococcus capitis Pseudomonas fluorescens Acinetobacter guillouiae Aeromonas hydrophila Delftia acidovorans Comamonas testosteroni Sphingomonas paucimobilis Staphylococcus epidermidis Micrococcus luteus Staphylococcus haemolyticus - 3) Conclusion
- Feeding planarians with inactivated malted yeast does not eliminate the human-pathogenic microorganisms present in Schmidtea mediterranea.
- d) Planarians Belonging to the Schmidtea mediterranea Species Fed with Baker's Yeast (Saccharomyces cerevisiae)
- 1) Material and Method
- The material and method of this test is the same as that implemented in example 1 of the patent application but by feeding the planarians exclusively with baker's yeast Saccharomyces cerevisiae and not exclusively with malted yeast (Saccharomyces cerevisiae+malt according to the invention).
- 2) Results of the Microbiota Analysis
- Planarians belonging to the Schmidtea mediterranea species fed exclusively with baker's yeast contain bacteria that are pathogenic for humans, namely:
-
TABLE 6 Human-pathogenic bacteria found in planarians fed with baker's yeast Aeromonas veroni Staphylococcus capitis Pseudomonas fluorescens Acinetobacter guillouiae Aeromonas hydrophila Delftia acidovorans Comamonas testosteroni Sphingomonas paucimobilis Staphylococcus epidermidis Micrococcus luteus Staphylococcus haemolyticus - 3) Conclusion
- Feeding planarians with baker's yeast does not eliminate the human-pathogenic microorganisms present in Schmidtea mediterranea.
- Planarians belonging to the Schmidtea mediterranea species are fed according to the same method as in Example 1 part a) with different foods without element of animal origin. The different foods tested are as follows: baker's yeast, spirulina, tofu, soy protein, soy milk, oatmeal or malt.
- The results obtained are reproduced in the table below.
- Platyhelminthes do not feed in a perennial way with any of these foods without element of animal origin. Surprisingly, flatworms do not accept feeding with malt unlike malted yeast. Feeding flatworms with each of the foods free of elements of animal origin, except malted yeast, does not eliminate the human-pathogenic microorganisms present in Schmidtea mediterranea.
- Surprisingly still, flatworms do not accept perennial feeding with baker's yeast (Saccharomyces cerevisiae) but accept feeding with malted yeast (Saccharomyces cerevisiae with malt), which differs from baker's yeast only by the presence of malt.
- 1. Preparation of Planarians
- About 400 flatworms (Schmidtea mediterranea) fed with malted yeast according to Example 1 (wet mass comprised between 0.1 g and 0.4 g) were starved for 2 weeks.
- The planarians were washed twice with 200 ml of sterile water (ceramic: microfiltration (0.2 micron), interior of the antibacterial ceramic, compacted activated carbon). The washed planarians were transferred to a tube and the water was removed then the planarians were frozen at −80° C.
- 2. Obtaining the Extract
- The tube containing the frozen planarians was placed on ice until thawed. 20 ml of sterile water (temperature 4° C.) was added to the thawed planarians. 1 cm of sterile glass ball (diameter 3 mm) was added to the tube (tube A).
- Tube A was mixed using a mechanical stirrer for 5 minutes at 2500 cycles/minute. The content of tube A was passed through a syringe equipped with a 23 g needle and placed in a new tube (tube B).
- 20 ml of sterile water (temperature of 4° C.) was added to tube A containing the glass beads and the residues which remained stuck to the beads. Tube A was again mixed using a mechanical stirrer for 5 minutes at 2500 cycles/minute. The content of tube A was again passed through a syringe equipped with a 23 g needle then transferred to tube B. Tube B now contains 40 ml of crude planarian extract.
- Tube B is centrifuged for 5 min at 3220 g at 4° C. then the supernatant of tube B was filtered through a 1.20 μm membrane (filtrate 1).
Filtrate 1 was then filtered on a 0.80 μm membrane (filtrate 2). Filtrate 2 was then filtered on a 0.45 μm membrane (filtrate 3). Filtrate 3 was then filtered on a 0.2 μm membrane (filtrate 4). Filtrate 4 only contained particles smaller than 0.2 μm. - The protein concentration of filtrate 4 was determined by absorbance at the wavelength of 280 nm. For 400 initial planarians (wet mass comprised between 0.1 g and 0.4 g) the protein concentration obtained was comprised between 17.5 and 20 mg of protein/mL.
- The filtrate 4 (corresponding to an aqueous extract freed from any insoluble solid debris larger than 0.2 μm) was freeze-dried and stored at 4° C. for subsequent use.
- Filtrate 4 was analyzed in triplicate by MALDI-TOF according to the protocol detailed below.
- MALDI-TOF Analysis Protocol
- A 1 μl sample of aqueous extract from example 4A was diluted to 1/20th with a mixture of trichloroacetic acid, acetonitrile and water and was deposited on an HCCA matrix. Then, 1 μL of HCCA saturated matrix was added on top, then the whole was dried for 10 minutes. The analysis of the extract was performed with a Maldi-Tof Microflex LT10 (Bruker) mass spectrometer. The results were collected with the MALDl Biotype RTC software.
- The spectra acquisition method comprised the following steps and characteristics:
-
- introduce the plate (Microflex target reference model 224989 called M5P 96) containing the depositions into the Microflex LT mass spectrometer,
- start the computer associated with the spectrometer to launch the analyzes and
- launch the acquisition of MALDl-TOF mass spectra.
- The parameters applied to the mass spectrometer were as follows: positive linear model Electrode 151: 20.00 kV, Electrode 152: 18.05 kV, Focusing electrode: 6 kV1 Laser frequency: 60 Hz, Detector gain: 8.8×, Post Ion Extraction (PIE): 120 ns, Mass range: from 700 to 20000 Da.
- The spectra were obtained using an automatic method controlled by the FLEXCONTROL® software from the manufacturer BRUKER DALTONICS® the parameters were as follows for each spot: number of series of 40 shots: 6 on different positions of the spot (6×40=240 spectra), for the shots to sweep the entire sample in a homogeneous way the acquisition is done on 6 different positions according to a hexagonal geometry, pre-shots: 10 shots at 40% of the maximum laser power are used to desalinate the sample (contamination by mineral salts), laser power: 30% to 45% regulated via the FLEXCONTROL® software, spectrum selection: over a mass range of 2000 to 20000 Da. The acquisition of the spectra is ultimately carried out using the BIOTYPER® software from the manufacturer BRUKER DALTONICS® which allows to apply the automatic method described above to a series of samples taking into account the criteria mentioned above and a quality score or validation score which represents the addition of 2 ratings nl+n2 (n1 being a function of the number of peaks and n2 a function of the signal/background noise ratio):
-
- nl is the rating assigned according to the number of characteristic peaks of the spectrum n, with: nl=0 for n::s: 8, nl=1 for 8<n::s: 27, nl=2 for 27<n:s; 43, nl=3 for 43<n:s; 78, nl=4 for 78<n:;; 86, nl=5 for 86<n:;; 110, nl=6 for 110<n, and
- n2 is the rating assigned according to the value of the signal-to-noise ratio (Rmax) of the peak of greatest intensity in the spectrum, with n2=0 for Rmax:s; 6.8, n2=1 for 6.8<Rmax::s: 26.8, n2=2 for 26.8<Rmax::s: 52.6, n2=3 for 52.6<Rmax::s: 208.6, n2=4 for 208.2<Rmax:::; 398.6, n2=5 for 398.6<Rmax::s: 1092.2, n2=6 for 1092.2<Rmax.
- A spectrum is taken into account if its validation score (nl+n2) is greater than 2.
- Results of MALDI-TOF Analysis
- The data are shown in Table 8 (m/z: mass to charge, intensity: signal intensity; S/N: signal to noise).
-
TABLE 8 Experiment 1Experiment 2 Experiment 3 m/z Intensity S/N m/z Intensity S/N m/z Intensity. S/N 2001 5051 8 2000.7 5566 8 2001.2 1706 7 2390.4 3699 5 2723.3 3988 7 2723.8 2062 9 2723.7 4012 8 3335.8 3074 5 3335.7 1224 5 3335.6 2812 5 3672.7 3390 7 3673.2 2021 9 3673.3 3533 9 3708.1 4153 10 3708.4 2804 13 3708.7 4596 13 4551.1 2822 7 3760.5 1500 7 3760.9 2701 6 4871.2 3613 10 4550.7 1414 7 4551.4 2604 7 5012.3 2930 8 4871.1 2254 11 4871.6 3185 10 5072.5 3321 9 5012.6 1683 9 5012.9 2746 8 5267.7 2351 6 5060 974 5 5060.4 2042 5 5646.8 7211 28 5072.8 2096 11 5072.8 3282 10 5870.1 2197 6 5268 1410 7 5268.3 2221 6 5890.7 2105 6 5647.1 5163 30 5647.6 6601 28 5906.5 2005 6 5870.4 1070 6 5871.3 1808 5 6393.6 5383 23 5890.8 1067 6 5891.4 1859 6 6415.4 1900 6 5906.7 1008 6 5907.7 1886 6 6432.8 4926 20 5965 901 5 5965.5 2019 6 6487 2204 7 6393.6 3673 24 6394.2 4603 21 6534.1 3192 12 6414.6 882 6 6433.5 4207 19 6556.8 4018 16 6433.2 3106 20 6487.8 2003 7 6577.9 1864 6 6487.1 1245 8 6535 2888 12 6674.1 5905 27 6534.4 1980 13 6557.6 3510 15 6695.2 1817 6 6557 2491 16 6675.2 4693 23 7347.6 7866 44 6674.5 3967 28 7306.6 1498 5 7369.5 2976 14 7348 6232 50 7349 7585 45 7418 10220 58 7369.7 2025 16 7369.9 2881 15 7438.6 3214 15 7418.4 7822 62 7419.5 8974 54 7471.5 2704 12 7472 1966 16 7472.7 2731 14 7492.2 2184 9 7523 4434 37 7524.1 5714 35 7522.9 5581 31 7542.1 1296 11 7568 1726 7 7541.6 2177 10 7569.3 1048 9 7588.1 3819 22 7564.9 1721 7 7587.1 2747 23 7606.4 1577 6 7586.4 3623 19 7754.2 616 5 7755.1 1452 6 7607 1645 6 8470.5 1655 17 8471.3 2189 15 8469.5 2390 16 8498.9 806 8 8499.6 1422 8 8498.3 1731 11 8525.6 870 9 8526.7 1394 8 8523.9 1798 11 8545.9 642 7 8547 1154 6 8544.4 1268 7 9395.7 741 9 9396.7 1148 9 9395.2 1143 8 14027.7 146 6 14031.1 223 5 - 1. Toxicity of the Planarian Aqueous Extract
- The cytotoxicity of the aqueous extract obtained in Example 3 (filtrate 4) was tested on HL60 human lymphocyte cells (ATCC CCL-240). The cells were contacted with different dilutions of the extract. Briefly, 5×104 cells/well (24-well plate) were cultured in RPMI medium (GibCoBRL) supplemented with fetal calf serum (10%) and penicillin and streptomycin (5000 U/ml, 5000 μg/ml respectively), at 37° C., and under a 5% CO2 atmosphere.
- At a dilution of 1:5 (that is to say 0.3 mg of protein/ml of extract) the extract caused cell death. The 1:20 (that is to say 75 μg of protein/ml of extract) and 1:100 (that is to say 15 μg of protein/ml of extract) dilutions did not affect cell viability (
FIG. 1 ). - 2. Effect of Planarian Aqueous Extract on Human Stem Cell Multiplication
- The cells used were human stem cells (ATCC CLS-300702). The cells were contacted with different dilutions of the extract. Briefly, 5×103 cells/well, on a 48-well plate, were cultured in DMEM/F12 medium (GibCoBRL) supplemented with fetal calf serum (10%) and penicillin and streptomycin (5000 U/ml, 5000 μg/ml respectively), at 37° C., and under 5% CO2 atmosphere. The results are shown in
FIG. 2A to D. Only a dilution (1/20;FIG. 2B ), which is comprised between 1:5 (FIG. 2A ) and 1:100 (FIG. 2C ), allowed a significant induction (*p<0.05) of human stem cell proliferation compared to untreated cells. The induction of multiplication was about 1.6 times.FIG. 2D shows the growth of human stem cells treated with the planarian aqueous extract diluted to 1/20th for 9 days and the control without treatment. The cells were stained with Giemsa. - 3. Measurement of the Effect of the Planarian Aqueous Extract on the Multiplication of Human Epithelial Cells
- The cells used were human epithelial cells (ATCC CCL-2). The cells were contacted with different dilutions of the extract. Briefly, 5×103 cells/well, on a 48-well plate, were cultured in DMEM medium (GibCoBRL) supplemented with fetal calf serum (10%) and penicillin and streptomycin (5000 U/ml, 5000 μg/ml respectively), at 37° C., and under a 5% CO2 atmosphere.
- A dilution (1/20;
FIG. 3B ), ranging from 1:5 (FIG. 3A ) to 1:100 (FIG. 3C ), allowed a significant induction (*p<0.05) of the proliferation of human epithelial cells compared to untreated cells. The induction of multiplication was about 1.8 times.FIG. 3D shows the growth of human epithelial cells treated with the aqueous extract diluted to 1/20th for 9 days and the control without treatment. The cells were stained with Giemsa. - 4. Effect of Planarian Aqueous Extract on Human Endothelial Cell Multiplication
- The cells used were human endothelial cells (ATCC CRL-1730). The cells were contacted with different dilutions of the extract. Briefly, 5×103 cells/well, on a 48-well plate, were cultured in DMEM medium (GibCoBRL) supplemented with fetal calf serum (10%) and penicillin and streptomycin (5000 U/ml, 5000 μg/ml respectively), at 37° C., and under a 5% CO2 atmosphere.
- A dilution (1/20;
FIG. 4B ), ranging from 1:5 (FIG. 4A ) to 1:100 (FIG. 4C ), allowed a significant induction (*p<0.05) of the proliferation of human endothelial cells compared to untreated cells. The induction of multiplication was about 1.38 times. - 5. Effect of the Aqueous Extract of Heat-Treated Planarian on the Replication of Human Stem Cells (ATCC CLS-300702), Human Endothelial Cells (ATCC CRL-1730), Human Epithelial Cells (ATCC CCL-2)
- A 1/20 dilution of the planarian aqueous extract obtained in Example 3 (filtrate 4) treated at 95° C. for 10 minutes is added to the human cells of interest. Cell multiplication was measured after 9 days.
- Heat inactivated the activity of the extract since no cell proliferation was observed, either for human stem cells (
FIG. 5A ), human epithelial cells (FIG. 5B ), or human endothelial cells (FIG. 5C ). The heat-inactivated planarian aqueous extract does not induce cell multiplication. - This suggests that the properties of the extract come from the proteins contained in the extract.
- 6. Effect of Planarian Aqueous Extract on Wound Healing of Human Stem Cell (ATCC CLS-300702) and Human Epithelial Cell (ATCC CCL-2) Cellular Layer
- Cells were grown to confluence until a cellular layer was formed. A 325 μm wide lesion of the cellular layer was made using a calibrated needle, then a 1/20 dilution of the planarian aqueous extract was added or not to the cell culture. Healing of the cellular layer (complete filling of the lesion with new cells) was monitored over time.
- The results are illustrated in the figures [
FIG. 6A ] and [FIG. 6B ]. - It was observed that for human stem cells, as for epithelial cells, the healing of the lesion of the cellular layer was almost complete after 24 hours, and the lesion was completely closed after 48 hours of treatment with the planarian aqueous extract diluted to 1:20th. In the absence of extract, healing was not complete after 48 hours.
- 7. Effect of Planarian Aqueous Extract on Gene Induction in Human Cells
- Human epithelial, endothelial (ATCC CRL-1730) and stem cells (ATCC CLS-300702) were treated with a 1/20th dilution of the planarian aqueous extract, then the expression of certain genes was measured by quantitative PCR. The expression was expressed in “fold change”. The higher the fold change, the more the gene is expressed.
- The results are shown in Table 9.
-
TABLE 9 Ratio of gene expression relative to control Genes Functions Epithelial cells Endothelial cells Stem cells CD44 hyaluronic acid 1.94 1.47 2.36 receptor/immunity/adhesion and cell migration TLR2 Immunity 3.21 2.95 6.04 TGFb cell proliferation 2.64 1.08 1.73 RunX1 multiplication, tissue cohesion, cell 2.7 0.4 9.38 differentiation PiwiL1 cell renewal 2.35 0.19 9.29 SGK1 UV protection and anti-oxidative 29 4.49 10.92 stress, photo-aging FOXO1 UV protection, photo-aging 2.25 0.13 8.43 BCL2 anti cell death 2.05 0.19 27.37 HMMR hyaluronic acid receptor, 1.5 1.59 2.56 associated cell mobility COL1A1 Collagen synthesis 3.14 0.3 2.07 FBL5 Healing 0 171.87 28.4 - Depending on the cell type, it was observed that the planarian aqueous extract induced healing genes, immune genes, cell renewal genes, cell migration genes, genes for protection against photo-aging, anti cell death genes, and hyaluronic acid receptor activating genes.
-
FIG. 1 illustrates the measurement of the cytotoxicity of the planarian aqueous extract on human lymphocyte cells. -
FIGS. 2A to 2D illustrate the measurement of the planarian aqueous extract on the multiplication of human stem cells. Only a dilution comprised (1/20, B) between 1/5 (A) and 1/100 (C) allows a significant induction (*p<0.05) of the proliferation of human stem cells compared to untreated cells.FIG. 2D shows the growth of human stem cells treated with the planarian aqueous extract diluted to 1/20 for 9 days and the control without treatment. The cells are stained with Giemsa. -
FIGS. 3A to 3D illustrate the measurement of the effect of the planarian aqueous extract on the multiplication of human epithelial cells. The cells used are human epithelial cells (ATCC CCL-2). A dilution (1/20; B) and 1:5 (A) and 1:100 (C) allows a significant induction (*p<0.05) of the proliferation of human epithelial cells compared to untreated cells.FIG. 3D shows the growth of human epithelial cells treated with the planarian aqueous extract diluted to 1/20 for 9 days and the control without treatment. The cells are stained with Giemsa. -
FIGS. 4A to 4C illustrate the measurement of the effect of the planarian aqueous extract on the proliferation of human endothelial cells. The cells used are human endothelial cells (ATCC CRL-1730). A dilution (1/20; B) and 1:5 (A) and 1:100 (C) allows a significant induction (*p<0.05) of the proliferation of human endothelial cells compared to untreated cells. -
FIGS. 5A to 5C illustrate the measurement of the effect of the aqueous extract of heat-treated planarian on the replication of human stem cells (ATCC CLS-300702), human endothelial cells (ATCC CRL-1730), human epithelial cells (ATCC CCL-2). A 1/20 dilution of the planarian aqueous extract is treated at 95° C. for 10 minutes is added to the human cells of interest and the multiplication of the cells is measured after 9 days. The heat inactivates the activity of the planarian aqueous extract since no cell proliferation is observed either for human stem cells (A), human epithelial cells (B), or human endothelial cells (C). The aqueous heat-inactivated planarian extract does not induce cell multiplication. -
FIGS. 6A and 6B illustrate the measurement of the effect of the planarian aqueous extract on the healing of a cellular layer of human stem cells and human epithelial cells. The human cells of interest are cultured to confluence until a cellular layer is formed. A 325 μm wide lesion of the cellular layer is made using a calibrated needle, then the planarian aqueous extract diluted to 1/20th is added or not to the cell culture. Healing of the cellular layer (complete filling of the lesion with new cells) is monitored over time. It can be seen that for human stem cells, as for epithelial cells, the healing of the lesion of the cellular layer is almost complete after 24 hours, and the lesion is completely closed after 48 hours of treatment with the planarian aqueous extract diluted to 1/20th. In the absence of treatment, healing is not complete after 48 hours.
Claims (16)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2008979A FR3113809A1 (en) | 2020-09-04 | 2020-09-04 | Flatworm and flatworm extract free of pathogenic microorganisms for humans |
FRFR2008979 | 2020-09-04 | ||
PCT/FR2021/051497 WO2022049340A1 (en) | 2020-09-04 | 2021-08-30 | Method for feeding a flatworm and flatworm extract free of human-pathogenic microorganisms |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230310513A1 true US20230310513A1 (en) | 2023-10-05 |
Family
ID=74125320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/024,682 Pending US20230310513A1 (en) | 2020-09-04 | 2021-08-30 | Method for feeding a flatworm and flatworm extract free of human-pathogenic microorganisms |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230310513A1 (en) |
EP (1) | EP4208179A1 (en) |
FR (1) | FR3113809A1 (en) |
WO (1) | WO2022049340A1 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111032125A (en) | 2017-07-21 | 2020-04-17 | 贝克顿迪金森法国公司 | Auxiliary injection device for injecting a component contained in a medical container with a low force |
-
2020
- 2020-09-04 FR FR2008979A patent/FR3113809A1/en active Pending
-
2021
- 2021-08-30 WO PCT/FR2021/051497 patent/WO2022049340A1/en unknown
- 2021-08-30 US US18/024,682 patent/US20230310513A1/en active Pending
- 2021-08-30 EP EP21777574.1A patent/EP4208179A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
FR3113809A1 (en) | 2022-03-11 |
WO2022049340A1 (en) | 2022-03-10 |
EP4208179A1 (en) | 2023-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101968894B1 (en) | Composition comprising Streptococcus pneumoniae strain and culture medium thereof | |
JP5718917B2 (en) | Novel Lactobacillus plantarum and composition containing the same | |
KR102207995B1 (en) | Composition for Anti-microbial, Anti-inflammation, and Skin Hydration Property Comprising Fermented Extract of Momordica charantia as Active Ingredient | |
US20100111927A1 (en) | Compositions Comprising Actinidia and Methods of Use Thereof | |
EP3508568B1 (en) | Leuconostoc holzapfelii strain having hair loss prevention, hair growth promotion or sexual function improvement effects, and composition comprising same | |
KR102253418B1 (en) | Composition comprising an exosome derived from skin lactic acid bacteria as an active ingredient | |
EP1858535A2 (en) | Compositions comprising actinidia and methods of use thereof | |
EP3508208A1 (en) | Composition, for preventing hair loss or promoting hair growth, comprising strains showing lipolysis effect | |
KR20170002846A (en) | Composition containing extract of soybean leaves for suppressing and preventing myopathy | |
KR101391911B1 (en) | Bee venom composition having improved growth rate and immune function | |
KR101963572B1 (en) | Composition for improving skin beauty comprising extract of fermented swallow's nest fermented with Aspergillus cristatus strain | |
US20230310513A1 (en) | Method for feeding a flatworm and flatworm extract free of human-pathogenic microorganisms | |
KR102118575B1 (en) | Composition for improving skin wrinkle and skin moisturizing comprising Enterococcus lactis as effective component | |
KR101491775B1 (en) | Composition for the growth inhibiting of antibiotic resistant hazardous microbes | |
KR101286266B1 (en) | Composition for hair loss prevention and/or hair growth promotion comprising fermented pruni cortex | |
KR102123030B1 (en) | A composition for improving diabetes or for use of antioxidant comprising yeast extract and a method for preparing the yeast extract | |
KR20190129528A (en) | Anti-oxidative and Anti-inflammatory Composition of Starfish Extract from Crossaster papposus japonicus and Preparation Method Thereof | |
CN116144521A (en) | Lactobacillus sakei AMP5104 strain and application thereof | |
KR100597612B1 (en) | A food composition comprising scrophularia buergeriana extract with anti-aging activity | |
KR101385191B1 (en) | Use of Cichorium intybus extracts for preventing, treating improving muscular atrophy | |
KR101894874B1 (en) | Anti-inflammation Composition Using Streptomyces fragili | |
KR20040074696A (en) | Scrophularia buergeriana extract with anti-aging activity and a composition containing the extract | |
US20210161973A1 (en) | Aqueous extract of ground material of planarian organisms | |
KR102316637B1 (en) | Bacillus subtilis strain derived from Centella asiatica and its use for improving skin conditions | |
KR102411243B1 (en) | Use of Calidifontibacter indicus to improve skin condition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GHIGO, ERIC, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RAOULT, DIDIER;FOURNIER, PIERRE EDOUARD;GHIGO, ERIC;AND OTHERS;SIGNING DATES FROM 20230216 TO 20230406;REEL/FRAME:063849/0185 Owner name: AIX-MARSEILLE UNIVERSITE, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RAOULT, DIDIER;FOURNIER, PIERRE EDOUARD;GHIGO, ERIC;AND OTHERS;SIGNING DATES FROM 20230216 TO 20230406;REEL/FRAME:063849/0185 Owner name: FONDATION MEDITERRANEE INFECTION, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RAOULT, DIDIER;FOURNIER, PIERRE EDOUARD;GHIGO, ERIC;AND OTHERS;SIGNING DATES FROM 20230216 TO 20230406;REEL/FRAME:063849/0185 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |